Abstract |
Twelve patients with chronic renal failure (CRF) requiring dialysis, 7 of whom were hypercalcaemic, were treated with 24,25-dihydroxycholecalciferol [24,25( OH)2D3; 10 micrograms daily for 3 months] or placebo and the treatment then crossed over for a further 3 months. Treatment with 24,25( OH)2D3 was associated with small but significant increments in the fractional rates of absorption of calcium (p less than 0.01) and phosphate (p less than 0.05) measured by a combined radioisotope test, but even during treatment, the absorption of both calcium and phosphate remained subnormal. A significant fall in immunoreactive parathyroid hormone (i-PTH) levels occurred during treatment (p less than 0.05) in the absence of significant changes in plasma ionised calcium and plasma phosphate levels. In 7 patients, treatment with 24,25( OH)2D3 converted parathyroid glands which were non-suppressible by calcium infusion before treatment to suppressible ones (greater than 50% suppression of i-PTH levels) at similar levels of ionised calcium. 24,25( OH)2D3 may have a role in the treatment of renal osteodystrophy, especially in patients with hypercalcaemic hyperparathyroidism.
|
Authors | Z Varghese, J F Moorhead, K Farrington |
Journal | Nephron
(Nephron)
Vol. 60
Issue 3
Pg. 286-91
( 1992)
ISSN: 1660-8151 [Print] Switzerland |
PMID | 1565181
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Parathyroid Hormone
- Phosphates
- Calcitriol
- Calcium
|
Topics |
- Adult
- Aged
- Calcitriol
(therapeutic use)
- Calcium
(blood, metabolism)
- Female
- Humans
- Intestinal Absorption
(drug effects)
- Kidney Failure, Chronic
(physiopathology)
- Male
- Middle Aged
- Parathyroid Hormone
(blood, metabolism)
- Phosphates
(blood, metabolism)
|